Proveca Ltd
Clare Gleeson has extensive work experience in various roles within the pharmaceutical and healthcare industry. Clare currently holds the position of Chief Technical Operations Officer at Proveca Ltd, starting in May 2022. Prior to this, they worked at Proveca as Head of Operations from December 2010 to June 2022.
In addition to their time at Proveca, Gleeson also founded Clare Gleeson Consulting, where they served as Director from November 2010 to 2016. Before that, they worked as a Development Programme Manager at Auralis, where they were responsible for managing development projects and supporting the sale of the company to Viropharma Inc. Clare then transitioned to Viropharma and assisted with integration activities.
Gleeson has also held positions at Healthcare Brands International Limited as Head of Product Development from August 2006 to September 2009, Reckitt Benckiser as Programme Manager from August 2003 to August 2006, Boots Healthcare International as Product Development Team Manager from August 1998 to February 2006, and Boots The Chemists as Group Technical Manager from 1996 to 1998.
Overall, Clare Gleeson's work experience showcases their expertise in technical operations, operations management, consulting, development program management, and product development within the pharmaceutical and healthcare industry.
Clare Gleeson obtained a BSc in Textile Technology from The University of Manchester, completing their studies from 1984 to 1987.
This person is not in any offices
Proveca Ltd
Proveca Ltd is a pharmaceutical company specialising in identifying, researching and licensing off-patent medicines with unmet priority health care needs, with a focus on the paediatric market. By developing the necessary formulations and clinical data required to obtain a Paediatric Use Marketing Authorisation (PUMA) these drugs will benefit froma period of 10 years' market protection (8 years of data and market protection plus 2 further years of market protection). In addition, where appropriate, Orphan Drug status (Orphan Drug) will be sought which affords a period of 10 years' market exclusivity to run concurrently.Value will be realised through commercialisation of the licensed medicine or an outright sale of the licence to a larger pharmaceutical company.